Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new pharmacological class of drugs for treating Type 2 diabetes. They improve the capacity of the organism to control glycemia by increasing the levels of active incretins. Their mechanism of action is thus radically different from those of other anti-diabetic drugs currently available. DDP-4 inhibitors use a physiological mechanism to control hyperglycemia, by stimulating the secretion of insulin from beta-cells, decreasing the secretion of glucagon from pancreatic alpha-cells, and at the same time reducing the production of glucose by the liver. DDP-4 inhibitors have shown significant efficacy in maintaining reduced levels of glycosylated hemoglobin for up to 1 year. In vitro and animal studies have shown that they can inhibit apoptosis of beta-cells and favor their regeneration and differentiation. The oral DPP-4 inhibitors vildagliptin, sitagliptin, and saxagliptin are efficacious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose. Lastly, they have substantial advantages with respect to other anti-diabetic drugs, since they involve a low risk of hypoglycemia and do not affect body weight.
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management / G. Crepaldi, M. Carruba, M. Comaschi, S. Del Prato, G. Frajese, G. Paolisso. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 30:7(2007 Jul), pp. 610-614.
|Titolo:||Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management|
CARRUBA, MICHELE (Secondo)
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||lug-2007|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/BF03346357|
|Appare nelle tipologie:||01 - Articolo su periodico|